Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

rom baseline to Week 4. Safety evaluations included incidence of adverse reactions, discontinuation due to adverse reactions, laboratory measures and body weight.

For the primary endpoint, both doses of ABILIFY demonstrated statistically significant improvement in symptoms when compared to placebo (p-value less than 0.0001) as measured by the mean change from baseline to endpoint (Week 4) on the Y-MRS Total Score. The efficacy of ABILIFY for the maintenance treatment of Bipolar I Disorder in the pediatric population has not been evaluated.

Approximately 80% of patients completed the four-week study (ABILIFY 10 mg: 86%; ABILIFY 30 mg: 78%; placebo: 77%). There was a low rate of discontinuation due to adverse reactions at Week 4 (ABILIFY: 7%; placebo: 2%).

During the study, the most commonly observed adverse reactions (greater than or equal to 5% in combined ABILIFY groups and at least twice the rate of placebo) associated with ABILIFY were: somnolence (ABILIFY: 23%; placebo: 3%), extrapyramidal disorder (ABILIFY: 20%; placebo: 3%), fatigue (ABILIFY: 11%; placebo: 4%), nausea (ABILIFY: 11%; placebo: 4%), akathisia (ABILIFY: 10%; placebo: 2%), blurred vision (ABILIFY: 8%; placebo: 0%), salivary hypersecretion (ABILIFY: 6%; placebo: 0%) and dizziness (ABILIFY: 5%; placebo: 1%). Four common adverse reactions had a possible dose-response relationship at Week 4: extrapyramidal disorder (ABILIFY 10 mg: 12.2%; ABILIFY 30 mg: 27.3%; placebo: 3.1%), somnolence (ABILIFY 10 mg: 19.4%; ABILIFY 30 mg: 26.3%; placebo: 3.1%), akathisia (ABILIFY 10 mg: 8.2%; ABILIFY 30 mg: 11.1%; placebo: 2.1%) and salivary hypersecretion (ABILIFY 10 mg: 3.1%; ABILIFY 30 mg: 8.1%; placebo: 0%). Children and adolescents might be more sensitive than adults in developing antipsychotic-related adverse events.(1)

In the study, weight gain greater than or equal to 7% change from baseline was seen in 3.2%, 9.4% and 3.3% for the ABILIFY 10 mg, ABILIFY 30 mg and placebo groups, res
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  XBiotech announced today interim results from its ... US for its anti-cancer agent Xilonix™. ... being evaluated in advanced colorectal cancer patients where ... endpoint of the study is overall survival, comparing ... population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... CALGARY, Alberta , September 2, 2014 ... der "State of the Art and Featured Research Session" ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, dass Dr. Jan ... beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 in ... In seinem Vortrag mit dem Titel " Effects of ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... , ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 2President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 3President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 4President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 5President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 6President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 12ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 13ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 14ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 15ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 16ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 17ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 18ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 19ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 20ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 21ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 22ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 23
(Date:9/2/2014)... September 02, 2014 Anti-aging is ... and services such as anti-wrinkle treatments and products, ... treatments, and breast augmentation becoming much sought after ... U.S.-based market intelligence firm Transparency Market Research, the ... will grow to USD 191.7 billion by 2019, ...
(Date:9/2/2014)... 02, 2014 Evolve Medical Clinics, ... primary and urgent care arena, is having its ... with a health fair the clinic is sponsoring. ... to assist patients in achieving high quality, convenient ... pricing structure is a groundbreaking change in healthcare. ...
(Date:9/2/2014)... 2014 When weather conditions are right, tornadoes ... leaving behind a path of destruction. In fact, the United ... of 1,253 tornadoes per year. Rainbow International offers the following ... tornado strikes., , Select a safe place ... your home with no windows to stay during the storm. ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... emerged a heartening development.The World Health Organisation (WHO) has ... based Institute for OneWorld Health, a non-profit drug firm, ... ,Paromomycin IM Injection is a cost-effective treatment ... parasitic disease after malaria. ,It is ...
... A new study has found that single tablets containing ... to controlling increasing blood pressure in people with ... ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients ... of researchers led by Ken Jamerson at the University ...
... on stem cells as a cure for infertility has made ... to grow mature sperm from adult stem cells, says Dr.Karim ... Dr. Nayernia, a professor of stem biology at the ... team had successfully coaxed the embryonic stem cells of mice ...
... Calcutta will reach out to more poor people with free ... the three healthcare units we have opened in Kolkata are ... target to reach out to more number of people by ... Gupta told a press conference Tuesday. ,"We have ...
... taken ill Wednesday after inhaling methane gas leaking from a colliery ... leak was reported early morning from the Bathdih colliery of Bharat ... ,The 10 people of Barari Basti area who fell ... to be in critical condition. ,BCCL officials have rushed ...
... girl dragged along by her headlocks, on the ground then, covering ... her head is smashed with a concrete block, blood oozes from ... heard. ,In the eyes of many in her ... was to love a boy from another religion. She was a ...
Cached Medicine News:Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:Single-tablet With Two Drugs may Help Control High BP Better 2Health News:Stem Cell Answer to Infertility in Five Years, Says Scientist 2Health News:Women in Iraq More Unsafe Than Ever 2
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
... and skull base surgery. Complete implant ... pediatric neurosurgery, bony defects of the ... regions, neuro trauma. Dedicated neuro/skull base ... one compact kit. MRI and CT ...
Ralk Hand Drill, with Jacobs chuck, wrench-locking, with axial channel for Kirschner wires, for twist drills up to 7 mm , for Kirschner wires up to 4 mm...
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs...
Medicine Products: